StockNow
Log in
U.S. Markets

Gilead (GILD) and Merck (MRK) announces that primary endpoint results showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir/lenacapavir was effective in adults living with HIV in ISLEND-1 and ISLEND-2 trials

StockNow breaking-news AI analysis

Gilead and Merck reported successful primary endpoint results for their once-weekly oral HIV treatment in ISLEND-1 and ISLEND-2 trials. Separately, Merck expanded a clinical collaboration for biliary tract cancer treatments.

2 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)